Teleflex Incorporated (TFX) Launches ARROW® JACC (Jugular Axillo-subclavian Central Catheter) With Chlorag+ard® Technology, the First and Only Long-Term Antimicrobial and Antithrombogenic CVC
9/20/2013 11:04:02 AM
LIMERICK, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical devices for critical care and surgery, has announced the launch of the new ARROW® JACC with Chlorag+ard® Technology. The ARROW® JACC (Jugular Axillo-subclavian Central Catheter) with Chlorag+ard® Technology is a small-french size antimicrobial and antithrombogenic catheter that is designed for both acute and long-term use. The ARROW® JACC employs Chlorag+ard® Technology as a weapon against thrombosis and infection for up to 30 days, effective against the full spectrum of bacterial and fungal pathogens. Approximately 250,000 patients acquire catheter-related bloodstream infections each year in the United States, with oncology, diabetic, critically ill and chronically ill patients at highest risk. According to the CDC, an estimated 30,000 to 62,000 patients die each year as a result of a catheter-related bloodstream infection.1 The ARROW® JACC with Chlorag+ard® Technology provides caregivers another tool to effectively and economically care for millions of patients.
Help employers find you! Check out all the jobs and post your resume.